Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
185 hedge funds and large institutions have $2.24B invested in Chinook Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 65 funds opening new positions, 59 increasing their positions, 42 reducing their positions, and 37 closing their positions.
76% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 37
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
58% more capital invested
Capital invested by funds: $1.42B → $2.24B (+$822M)
40% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 42
18% more funds holding
Funds holding: 157 → 185 (+28)
26% less call options, than puts
Call options by funds: $10.6M | Put options by funds: $14.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$54.7M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$39.1M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$32.4M |
| 4 |
TAL
TIG Advisors LLC
New York
|
+$22.9M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$20.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$69.5M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$59.1M |
| 3 |
O
OrbiMed
New York
|
-$47M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$40.3M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$31.7M |
KDNY Hedge Fund Activity: Q2 2023 in Review
185 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q2 2023, worth a combined $2.24B — up 58% from $1.42B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new KDNY positions and 37 closed out — a net gain of 28 holders — while 59 added to existing stakes and 42 trimmed.
The largest buyer was Alpine Associates Management, opening a new position worth an estimated $54.7M. The largest seller was Deep Track Capital, exiting entirely with an estimated $69.5M sold.
- 185 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q2 2023, up from 157 in Q1 2023.
- Funds reported $2.24B of Chinook Therapeutics, Inc. Common Stock stock for Q2 2023, up 58% quarter-over-quarter.
- 65 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q2 2023 and 37 closed out, a net change of +28 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q2 2023 was Alpine Associates Management, an estimated $54.7M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q2 2023 was Deep Track Capital, an estimated $69.5M sold.
Based on aggregated 13F filings for Q2 2023.